Ask any parent of a four-year-old with amblyopia about the eye patch, and you will hear the same story. Tears at breakfast. The patch ripped off at kindergarten. A bin full of adhesive strips that never lasted the prescribed two hours. For centuries, the treatment for lazy eye — a neural disorder affecting up to five percent of all children — has relied on covering the stronger eye and hoping the weaker one catches up. The logic is unimpeachable. The execution is a disaster. Compliance rates languish around 50 percent. Even among children who endure the ordeal, 40 percent never achieve normal vision, and more than a third of those who do improve will eventually regress.

The patch, in short, is a treatment that works in the consulting room but fails in the living room.

Clinicians who treat amblyopia know this frustration intimately. One US paediatric ophthalmologist described it as trying to reason with a four-year-old who does not want a patch over their eye while playing outside. Another, at the Children’s Eye Institute of Savannah, put it more bluntly: parents are desperate for any modern alternative. The problem is not that doctors lack effective therapies. It is that children — understandably — refuse to use them. When NovaSight, an Israeli startup, began enrolling patients who had previously failed traditional patching in its CureSight digital therapy programme, the clinicians involved reported something they rarely saw: children who actually wanted to do their treatment, and parents whose relief was palpable.

CureSight is one of a cluster of technologies emerging from Israeli startups that are reimagining amblyopia treatment from the ground up. Where patching shuts down one eye to train the other, these companies train both eyes simultaneously, exploiting the very binocular integration that amblyopia disrupts.

Developed by NovaSight, based at Airport City near Ben Gurion, the CureSight system has children watch whatever streaming content they choose — Netflix, YouTube, cartoons — through red-blue treatment glasses connected to a tablet with a built-in AI eye-tracker. The red lens selectively blurs only the centre of the dominant eye’s visual field, while the blue lens delivers a crisp image to the lazy eye. The brain, forced to rely on the weaker eye for fine detail, gradually relearns to integrate both. The child barely notices the intervention. The parents notice something else entirely: their child is actually doing the treatment.

The clinical data is now substantial. In the 103-patient pivotal trial across six Israeli hospitals — including Sheba Medical Center — CureSight did not merely match patching; it outperformed it on key measures. Seventy-nine percent of children in the CureSight group improved by two or more lines of visual acuity, compared with 61 percent in the patching group. And here is the detail that should give every paediatric ophthalmologist pause: the CureSight group achieved those superior results in roughly half the total treatment time — 120 hours over 16 weeks, versus 224 hours of patching. Adherence hit 93 percent.

A subsequent 149-patient randomised controlled trial, published in the American Journal of Ophthalmology, confirmed that CureSight delivered significantly greater improvements in visual acuity than patching. And a one-year follow-up of the pivotal cohort showed the gains held, with significant improvements in both visual acuity and stereoacuity maintained at 52 weeks post-treatment.

The device has since received FDA 510(k) clearance, CE marking in Europe, and approval from China’s NMPA. Three dedicated CPT reimbursement codes from the American Medical Association are now in place, and over 250 US eye care providers — including clinicians at Duke, the Cleveland Clinic, and Seattle Children’s Hospital — have joined the CureSight referral programme, generating more than 650 patient referrals. NovaSight has raised $26 million to date.

NovaSight is not the only Israeli company attacking this problem, and the diversity of approaches is itself remarkable. Dr. Omry Ben-Ezra, an Israeli family physician, invented Amblyz — electronically controlled spectacle lenses that intermittently occlude the stronger eye using liquid crystal technology, creating what amounts to interval training for the visual cortex. Early clinical testing at three Israeli medical centres showed strong compliance and an average improvement of 3.5 lines over nine months; a subsequent US randomised trial found visual outcomes equivalent to patching, though compliance rates were comparable rather than superior.

Meanwhile, Medisim’s BinoVision goggles stream separately manipulated views of the same image to each eye, and in clinical trials at Tel Aviv Medical Center achieved faster visual improvement than patching, with gains that held at nine-month follow-up. Three startups, three distinct mechanisms — gaze-tracked selective blur, intermittent electronic occlusion, dichoptic goggle stimulation — yet all converging on the same insight: the binding constraint on amblyopia outcomes was never the science. It was always the child.

The competitive landscape is now global. Boston-based Luminopia uses a VR headset loaded with children’s television shows to deliver dichoptic therapy, received its own FDA approval in 2021, and expanded its age range to children up to 12 in 2025 — the first FDA clearance for an amblyopia treatment in that bracket in over two decades. A Japanese multicenter trial launching in 2026 is testing VR-based amblyopia games with hand-tracking controllers. Israel, with roughly 70 ophthalmology startups — reportedly more than any single region worldwide — helped catalyse a field that is now moving fast.

But it is worth pausing on what these Israeli companies actually accomplished. They did not discover a new disease mechanism. They did not identify a novel drug target. They solved a problem that every paediatric ophthalmologist has known about for decades but accepted as intractable: how to deliver a well-understood therapy through the hands of a reluctant preschooler and into the neural pathways that matter, during the narrow developmental window before the damage becomes permanent.

And that developmental window itself may soon cease to be a constraint. In December 2025, neuroscientists at MIT’s Picower Institute published research in Cell Reports showing that temporarily anesthetising the retina of the amblyopic eye for just 48 hours could restore balanced visual input in the brain — in adult mice, well past the critical period when conventional treatment fails. The mechanism is striking: silencing the retina triggers burst firing in the thalamus that mimics the neural patterns seen before birth, essentially rebooting the visual system to a developmental state. The finding has already been replicated across species, and primate trials are underway. If the Israeli startups have solved the compliance problem in children, MIT’s Mark Bear and his team may be on the path to dissolving the age barrier entirely.

[https://picower.mit.edu/news/mit-study-shows-how-vision-can-be-rebooted-adults-amblyopia]

Amblyopia affects an estimated 100 million people worldwide, and the global treatment market — currently valued at over $4 billion — is projected to exceed $5.5 billion by the end of the decade, driven in significant part by the digital therapeutics these Israeli companies pioneered. For too many of those 100 million, the only thing that ever stood between a child and a lifetime of diminished vision was a small adhesive patch and a prayer for compliance. That is changing — and not just for children.

The pirate patch had a good run. But it is time for it to walk the plank.

© The Times of Israel (Blogs)